Discussions with leaders: David Mankoff talks with Jonathan Allis, a leader in the radiopharmaceutical industry, about his career and latest efforts as founding chief executive officer of Blue Earth Diagnostics.
Page 749
T.R.U.E. AI checklist: Buvat and Orlhac encourage consideration of 4 key questions to facilitate identification of ground-breaking and/or innovative artificial intelligence–based contributions in nuclear medicine.
Page 752
ARTnet collaboration: Francis and colleagues look at the successful efforts of the Australasian Radiopharmaceutical Trials Network, formed in 2014 to promote and facilitate innovative clinical research in imaging and therapy.
Page 755
Introduction to statistical concepts: Pugh and Torres-Saavedra provide an educational focus on basic statistical concepts—such as hypothesis testing, confidence intervals, parametric versus nonparametric tests, multiplicity, and diagnostic testing—that form the building blocks of research.
Page 757
PARP-1 and beyond: Puentes and colleagues review recent innovations in molecular imaging of DNA damage and repair, with an emphasis on poly[adenosine diphosphate ribose]polymerase-1 as an imaging target and predictive biomarker of response to therapy.
Page 765
Vaccine passports and the law: Cope and Stremitzer offer perspective on international requirements for proof of COVID-19 and their importance in achieving global herd immunity.
Page 771
Dynamic PSMA PET/CT and renal masses: Golan and colleagues examine the performance of dynamic 68Ga-prostate-specific membrane antigen-11 PET/CT evaluation in a series of patients with newly diagnosed and localized renal masses.
Page 773
68Ga-FAPI PET in PDAC: Röhrich and colleagues describe the clinical impact of PET/CT imaging using 68Ga-labeled fibroblast activation protein inhibitors in patients with primary or progressive/recurrent pancreatic ductal carcinoma.
Page 779
ABT-806i against EGFR: Gan and colleagues assess the safety, biodistribution, and pharmacokinetics of 111In-radiolabeled ABT-806, a tumor-specific antibody targeting the epidermal growth factor receptor, and the effects of repeated doses on receptor occupancy in patients with advanced cancers.
Page 787
α- versus β-therapy in multiple myeloma: Minnix and colleagues compare the potential therapeutic efficacy of β- and α-emitter radioimmunotherapy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multiple myeloma.
Page 795
18F-AraG profiling of tumors: Levi and colleagues investigate 18F-arabinosyl guanine PET as a noninvasive tool that can profile tumors on the basis of CD8+ cells and evaluate the immunomodulatory effects of chemotherapy.
Page 802
18F-FDG PET and NEN risk stratification: Binderup and colleagues assess the long-term prognostic value of 18F-FDG PET imaging for risk stratification of neuroendocrine neoplasms and compare this to World Health Organization tumor grading classification.
Page 808
Rapid infusion in PRRT: Ebbers and colleagues document the safety of an infusion time of less than 5 min for peptide receptor radionuclide therapy with 177Lu-labeled somatostatin analogs in patients with somatostatin receptor–expressing tumors.
Page 816
Automatic PCA tumor segmentation: Kostyszyn and colleagues detail the development of a convolutional neural network for automated contouring of intraprostatic gross tumor volume in 68Ga-PSMA and 18F-PSMA PET imaging.
Page 823
67CuSarbisPSMA radionuclide therapy: McInnes and colleagues report on studies of the therapeutic potential of 67Cu-CuSarbisPSMA in a prostate-specific membrane antigen–positive tumor model.
Page 829
Glucagon receptor PET in humans: Eriksson and colleagues describe the biodistribution and dosimetry of 68Ga-Tuna-2, developed to provide a noninvasive imaging marker for the glucagon receptor, in individuals with type 2 diabetes.
Page 833
Optoacoustic imaging of GLP-1R: Roberts and colleagues review the development and in vivo validation of a broad-spectrum and high-absorbance near-infrared optoacoustic contrast agent, E4x12-Cy7, for glucagonlike peptide-1 receptor imaging of small pancreatic islets in animal models.
Page 839
18F-Flurpiridaz MPI in smaller LVs: Sevag Packard and colleagues compare the diagnostic performances of myocardial perfusion imaging with 99mTc-labeled SPECT and18F-flurpiridaz PET according to left ventricle size as part of a larger clinical trial.
Page 849
PET and neuropathologic staging: Blazhenets and colleagues validate imaging-based patterns of glucose metabolism and amyloid deposition related to conversion from mild cognitive impairment to Alzheimer disease against neuropathologic findings.
Page 855
uExplorer performance evaluation: Spencer and colleagues present a detailed physical characterization of the uExplorer total-body PET/CT system based on National Electrical Manufacturers Association NU-2-2018 and a new set of metrics characterizing total-body axial field of view.
Page 861
cGAN-derived PET navigators: Shiyam Sundar and colleagues describe development of a motion-correction approach aided by conditional generative adversarial network methodology to allow data-driven determination of involuntary subject motion during dynamic 18F-FDG brain studies.
Page 871
- © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.